Eli Lilly and Company

Eli Lilly closed near the top of its 52-week range, supported by a 49.6% revenue jump and a 94.6% earnings surge from the prior year. The net margin of 33.5% reflects the pricing power of its GLP-1 franchise, which continues to drive volume. At a P/E of 41.8, the stock trades at a premium that the growth numbers partly justify. The Alpha Score of 73.2 is anchored by momentum and quality scores of 87 each, while value at 61.4 and sentiment at 50 suggest the market is already pricing in the trajectory. The next catalyst is the quarterly earnings report due in late April, where investors will watch for updates on manufacturing capacity and the launch timeline for next-generation obesity treatments.

Eli Lilly closed near the middle of its 52-week range, a wide band that reflects the stock's split between blockbuster drug momentum and a P/E north of 41. Revenue jumped 49.6% year over year, with EPS up 94.6% — numbers that justify the premium for many holders. Net margin of 33.5% is among the best in large-cap pharma. The Alpha Score of 73.2 is driven by momentum at 86.9 and quality at 87. Value scores a middling 61.4, and sentiment sits at 50, suggesting the market is pricing in the growth but not getting euphoric. The question for the next quarter is whether Mounjaro and Zepbound can sustain the pace as competition from Novo Nordisk's oral candidates and other GLP-1 entrants gets closer. Earnings due in early May will be the next real test.

Eli Lilly sits near the top of its 52-week range at $1,249.45, a reflection of the revenue and earnings acceleration that has defined the past year. Revenue jumped 49.6% year over year, while EPS surged 94.6%. Net margins hit 33.5%, among the widest in pharma. The Alpha Score of 73.2 is driven by momentum at 86.9 and quality at 87. Value scores a middling 61.4, and sentiment sits at 50 — neutral. The P/E of 41.79 is elevated, but the growth trajectory has kept the multiple in check. The next catalyst is the Q2 earnings report in early August, where investors will look for continued uptake of Zepbound and Mounjaro. Any pipeline setback could test the $1,000 support level.

Eli Lilly sits near the top of its 52-week range, up roughly 100% from the low. Revenue grew 49.6% year over year, EPS jumped 94.6%. Net margin of 33.5% reflects the pricing power of its GLP-1 franchise. The P/E of 41.79 is elevated, but the quality sub-score of 87 in the Alpha Score suggests the earnings stream is durable. Momentum scores 77.5, value 61.4. Sentiment is a neutral 50, implying the stock is neither crowded nor ignored. The next catalyst is the Q2 earnings report due in early August, where Mounjaro and Zepbound sales will be the focus. Any miss on volume or pricing could test the $1,100 support level. For now, the fundamentals support the premium.

Eli Lilly shares sit near the top of their 52-week range, a reflection of the earnings story that has made the stock a healthcare heavyweight. EPS surged 128.8% year over year, and revenue grew 47.4%. Net margins hit 35%, placing Lilly among the most profitable large-cap pharma names. The quality sub-score of 87 is the strongest pillar of its Alpha Score, while momentum at 75.6 confirms the trend is intact. The P/E of 42.8 is steep, but value scores 60.8 — not distressed, just priced for the growth trajectory. The market is paying up for the GLP-1 franchise and the pipeline beyond tirzepatide. The one soft spot is sentiment, which sits at 50 — neutral, suggesting no euphoric overhang. What to watch: next quarterly results, due in early May. The key question is whether supply expansions for Mounjaro and Zepbound can keep revenue growth above 40%. Any pipeline update on next-generation obesity candidates could reset sentiment higher.